Management of Early Onset Neonatal Septicaemia: Selection of Optimal Antibacterial Regimen for Empiric Treatment
Information source: University of Tartu
Information obtained from ClinicalTrials.gov on June 20, 2008 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Early Onset Neonatal Sepsis
Phase: N/A
Status: Completed
Sponsored by: University of Tartu Official(s) and/or principal investigator(s): Irja Lutsar, MD, PhD, Study Chair, Affiliation: University of Tartu
Summary
A prospective two-center antibiotic regimen switch study will be conducted to compare the
clinical efficacy of two antibiotic regimens - penicillin/gentamicin versus ampicillin/gentamicin - in the empirical treatment of early onset neonatal sepsis. The
influence of either regimen on bowel colonization pattern and on the development of
antibiotic resistance of gut microflora will also be assessed. The primary endpoint is the
need for a change in antibacterial treatment within 72 hours of therapy, based on pre-defined
criteria. Secondary endpoints will be the incidence rate and etiology of early and late onset
neonatal sepsis and susceptibility pattern of causative microorganisms; mortality rate within
60 days; duration of hospitalization in NICU; duration of artificial ventilation;
colonization pattern and susceptibility of colonizing bacteria (including resistance to
empiric antibiotic regimen).
Clinical Details
Official title: Comparative Study of Two Antibiotic Regimen - Penicillin G/Gentamicin Versus Ampicillin/Gentamicin in Empirical Treatment of Early Onset Neonatal Septicaemia
Study design: Cohort, Prospective
Detailed description:
A prospective randomized two-centre antibiotic regimen switch study will be conducted in the
NICU-s of Tartu University Clinics and of Tallinn Children's Hospital. Initially all patients
who need empiric treatment for early onset neonatal sepsis (as defined by Schrag et al. 2002)
in Tartu will be treated with penicillin/gentamicin and those in Tallinn with
ampicillin/gentamicin. When half of the needed subjects have been recruited, departmental
antibiotic regimen will be switched so that ampicillin is used in Tartu and penicillin in
Tallinn. Based on the present patient population and hospitalization rate, about 120-150
babies, eligible for the study will be admitted to either units every a year.
In all subjects predefined pre- and intranatal risk factors of infection will be registered.
During the NICU stay laboratory and clinical signs of infection, need for respiratory support
and vasoactive therapy, enteral and parenteral nutrition will be recorded.
Blood, CSF and urine cultures will be taken according to the routine of the ward but
certainly before every change in antibacterial treatment. For colonization studies
nasopharyngeal or tracheal and anal swabs will be collected from all neonates admitted during
the study period on admission and thereafter biweekly until discharge from the NICU or until
the 60th day of treatment. A separate protocol will be followed for microbiological
investigations.
The endpoints:
The primary endpoint is the need for a change in antibacterial treatment within 72 hours. In
discussions with clinical experts in both wards the following criteria for the change in
antibacterial treatment were defined:
1. proven or suspected meningitis or abdominal infection
2. isolation from a relevant site of the mother or an infant of a microorganism, resistant
to initial empiric treatment regimen in babies with early onset neonatal sepsis or
septic shock
3. deterioration of the clinical status on initial antibiotic regimen and suspected/proven
neonatal sepsis
4. suspected/proven late onset sepsis or nosocomial infection (defined as the development
of clinical/ laboratory signs of infection at postnatal age of 72 hours or more)
5. other situations, where the treating physician considers change in antibiotic regimen
necessary - the reasons will be recorded in the case report form Patients, who die
before 72 hours or in whom the antibacterial therapy is changed for other than the
above-mentioned reasons, will be handled as treatment failures.
Secondary endpoints will be the following:
- incidence rate and etiology of early and late onset neonatal sepsis, susceptibility
pattern of causative microorganisms
- incidence rate and etiology of nosocomial sepsis, susceptibility pattern of causative
microorganisms
- mortality rate within 60 days
- duration of hospitalization in NICU stay
- duration of artificial ventilation
- colonization pattern and susceptibility of colonizing bacteria (including resistance to
empiric antibiotic regimen).
Eligibility
Minimum age: N/A.
Maximum age: 72 Hours.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- All neonates, admitted to the study NICU-s at the age of less than 72 hours and
needing early empiric antibiotic treatment according to pre-defined criteria as
described by Schrag et al. (2002)
Exclusion Criteria:
- Subjects, who on clinical or other indications (e. g. suspected/proven meningitis or
abdominal cavity infection, isolation of resistant bacteria from the mother of a
neonate with severe sepsis) need antibiotic treatment other than specified in the
study protocol and infants who are likely to be transferred to other units within 24
hours.
Locations and Contacts
Tartu University Clinics, Department of Paediatric Intensive Care, Tartu 50411, Estonia
Tallinń's Childrens Hospital, Paediatric Intensive Care Unit, Tallinn, Estonia
Additional Information
Starting date: August 2006
Ending date: December 2007
Last updated: May 27, 2008
|